Citicoline
- Generic Name
- Citicoline
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H26N4O11P2
- CAS Number
- 987-78-0
- Unique Ingredient Identifier
- 536BQ2JVC7
- Background
Citicoline is a donor of choline in biosynthesis of choline-containing phosphoglycerides. It has been investigated for the treatment, supportive care, and diagnosis of Mania, Stroke, Hypomania, Cocaine Abuse, and Bipolar Disorder, among others.
- Indication
主要用于急性颅脑外伤和脑手术后的意识障碍，以及脑卒中而致偏瘫的患者；也用于耳鸣及神经性耳聋、急性中毒、感染、大面积脑梗死所致的昏迷和意识障碍、帕金森病、急性胰腺炎；对缺血性脑血管病和血管性痴呆也有一定疗效,但对颅内出血引起的意识障碍效果较差。
- Associated Conditions
- Degenerative Brain Disorder, Parkinsonian Syndromes
- Associated Therapies
- -
Cognizin Citicoline Dosing in a Healthy Adolescent Male Population
- Conditions
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- Deborah Yurgelun-Todd
- Target Recruit Count
- 84
- Registration Number
- NCT01582113
- Locations
- 🇺🇸
The Brain Institute, University of Utah, Salt Lake City, Utah, United States
Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)
- Conditions
- Interventions
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- Deborah Yurgelun-Todd
- Registration Number
- NCT01515917
Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.
- Conditions
- Interventions
- First Posted Date
- 2011-07-07
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- Clinical Institute of the Brain, Russia
- Target Recruit Count
- 30
- Registration Number
- NCT01388738
- Locations
- 🇷🇺
Clinical Institute of Brain, Ekaterinburg, Sverdlovsk region, Russian Federation
Citicoline Treatment of Methamphetamine Dependence
- First Posted Date
- 2009-07-31
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- Perry Renshaw
- Target Recruit Count
- 104
- Registration Number
- NCT00950352
- Locations
- 🇺🇸
The Brain Institute of the University of Utah, Salt Lake City, Utah, United States
CDP-Choline and Working Memory After TBI: A Neuroimaging Study
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Patricia M. Arenth
- Target Recruit Count
- 19
- Registration Number
- NCT00727246
- Locations
- 🇺🇸
University of Pittsburgh, Department of Physical Medicine & Rehabilitation, Pittsburgh, Pennsylvania, United States
Citicoline for Bipolar 1 Disorder and Cocaine Dependence
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 130
- Registration Number
- NCT00619723
- Locations
- 🇺🇸
Exchange Park Center, American General Building (Bass)- PNE: FL8, STE 828, Dallas, Texas, United States
Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT)
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2012-12-19
- Target Recruit Count
- 1213
- Registration Number
- NCT00545662
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸University of Maryland, Baltimore, Baltimore, Maryland, United States
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2018-04-11
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 43
- Registration Number
- NCT00509067
- Locations
- 🇺🇸
Washington Veterans Affairs Medical Center, Washington, District of Columbia, United States
Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases
- Conditions
- Interventions
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Fondazione G.B. Bietti, IRCCS
- Target Recruit Count
- 60
- Registration Number
- NCT00404729
- Locations
- 🇮🇹
Fondazione G.B. Bietti- IRCCS, Rome, Italy
🇮🇹Fondazione G.B. Bietti-IRCCS, Rome, Italy
A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence
- Conditions
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00377299
- Locations
- 🇺🇸
Psychoneuroendocrine Research Program, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.